Abstract: A mesoporous silica nanoparticle controlled release system, a preparation method thereof and an application thereof, and specifically provides a mesoporous silica nanomaterial that can be used for controlled release is disclosed. The mesoporous silica nanomaterial that can be used for controlled release comprises a mesoporous silica nanoparticle functionalized by means of a polyhydroxy compound and a nanoparticle plugging agent functionalized by means of a phenylboronic acid compound. When substrate concentration is relatively low, the nanomaterial achieves “zero early release”; when substrate concentration is relatively high, mesoporous pores blocked by the plugging agent are opened and active ingredients are released. The nanomaterial can be loaded into microneedles and microneedle array patches used to treat diabetes or to control blood sugar levels in patients.

Abstract: Provided are applications of a thiazole derivative in treating virus infection and in the preparation of drugs for treating virus infection.

Abstract: The present invention relates to applications of a novel thiazole derivative in treating ulcerative colitis and in the preparation of drugs for treating ulcerative colitis.

Abstract: The present invention relates to a pteridinone derivative serving as an EGFR inhibitor and use thereof. Specifically, the present invention relates to a compound represented by the following formula I, pharmaceutical composition comprising the compound of the following formula I, and use of the compound in preparation of drugs for treating EGFR-mediated diseases or inhibiting EGFR.

Abstract: The present invention provides a compound as represented by formula I, or a pharmaceutically acceptable salt or ester, a prodrug, an optical isomer, a stereoisomer, or a solvate thereof. The compound provided by the present invention can be used for preparing drugs for preventing or treating hypertension, or hypertension-related diseases, or pulmonary hypertension, or pulmonary hypertension-related diseases. The compound provided by the present invention has a different mechanism from existing drugs for treating hypertension and pulmonary hypertension, thereby laying a new material foundation for the development of drugs for treating hypertension and pulmonary hypertension.

Abstract: Provided is a selective JAK2 inhibitor and application thereof. In particular, it relates to the compound of the following Formula (I), and the use of the compound in the treatment of JAK2-mediated related diseases and in the preparation of the medicament for treating JAK2-mediated related diseases.

Abstract: Related to a quinazoline compound serving as an EFGR triple mutation inhibitor and applications thereof. Specifically, disclosed are a compound as represented by the following formula (I), a pharmaceutical composition comprising the compound of formula (I), and applications of the compound in treating a related disease mediated by EGFR and in a medicament for treating the related disease mediated by EGFR.

Abstract: A thiazole derivative serving as a DHODH inhibitor, and applications thereof. The present invention specifically relates to a compound represented by formula I, a pharmaceutical composition containing the compound represented by formula (I), and applications of the compound in the preparation of drugs for treating diseases mediated by the DHODH or drugs for inhibiting the DHODH.

Abstract: The present invention relates to six-membered ring benzo derivatives as a DPP-4 inhibitor and a use thereof. In particular, the present invention relates to a compound as shown in formula I, a pharmaceutical composition containing the compound as shown in formula I and a use of the compound in the preparation of drugs for treating DPP-4 related diseases or inhibiting DPP-4.

Abstract: A thiazole derivative serving as a DHODH inhibitor, and applications thereof. The present invention specifically relates to a compound represented by formula I, a pharmaceutical composition containing the compound represented by formula (I), and applications of the compound in the preparation of drugs for treating diseases mediated by the DHODH or drugs for inhibiting the DHODH.

Abstract: The present invention relates to applications of a novel thiazole derivative in treating ulcerative colitis and in the preparation of drugs for treating ulcerative colitis.

Abstract: Provided are applications of a thiazole derivative in treating virus infection and in the preparation of drugs for treating virus infection.

Abstract: The present invention relates to a pteridinone derivative serving as an EGFR inhibitor and use thereof. Specifically, the present invention relates to a compound represented by the following formula I, pharmaceutical composition comprising the compound of the following formula I, and use of the compound in preparation of drugs for treating EGFR-mediated diseases or inhibiting EGFR.

Abstract: A semi-automatic foot-pedal device is provided, which includes a panel and a pedal-connecting component connected with the panel. The pedal-connecting component includes an upper bracket, a left bracket, a lower bracket, a right bracket and an elastic unit; when the pedal-connecting component is in a closed state, the panel moves away from the upper bracket to transform the pedal-connecting component into an elastically spread state under a force on the panel in a downward direction and the elastic unit generates pushing force toward its two opposite directions; when the pedal-connecting component is in a spread state, the panel moves towards the upper bracket to transform the pedal-connecting component into an elastically closed state under a force on the panel in an obliquely-upward direction and the elastic unit generates pushing force toward its two opposite directions.

Abstract: The present invention relates to six-membered ring benzo derivatives as a DPP-4 inhibitor and a use thereof. In particular, the present invention relates to a compound as shown in formula I, a pharmaceutical composition containing the compound as shown in formula I and a use of the compound in the preparation of drugs for treating DPP-4 related diseases or inhibiting DPP-4.

Abstract: A semi-automatic foot-pedal device is provided, which includes a panel and a pedal-connecting component connected with the panel. The pedal-connecting component includes an upper bracket, a left bracket, a lower bracket, a right bracket and an elastic unit; when the pedal-connecting component is in a closed state, the panel moves away from the upper bracket to transform the pedal-connecting component into an elastically spread state under a force on the panel in a downward direction and the elastic unit generates pushing force toward its two opposite directions; when the pedal-connecting component is in a spread state, the panel moves towards the upper bracket to transform the pedal-connecting component into an elastically closed state under a force on the panel in an obliquely-upward direction and the elastic unit generates pushing force toward its two opposite directions.

Abstract: Provided are a pteridine ketone derivative used as an EGFR, BLK, and FLT3 inhibitor and applications thereof. Specifically, provided are a compound of the following formula I, a pharmaceutical composition containing the compound of the formula I, and use of compound in preparing medicine for treating diseases mediated by EGFR, BLK, or FLT3 or inhibiting EGFR, BLK, and FLT3.

Abstract: A semi-automatic foot-pedal device is provided, which comprises a panel and a pedal-connecting component connected with the panel. The pedal-connecting component comprises an upper bracket, a left bracket, a lower bracket, a right bracket and an elastic unit; when the pedal-connecting component is in a closed state, the panel moves away from the upper bracket to transform the pedal-connecting component into an elastically spread state under a force on the panel in a downward direction; when the pedal-connecting component is in a spread state, the panel moves towards the upper bracket to transform the pedal-connecting component into an elastically closed state under a force on the panel in an obliquely-upward direction. The semi-automatic foot-pedal device of the present disclosure has a novel structure, and does not need a conventional motor system, so it saves the electric power and is safer to use.

Abstract: A semi-automatic foot-pedal device is provided, which comprises a panel and a pedal-connecting component connected with the panel. The pedal-connecting component comprises an upper bracket, a left bracket, a lower bracket, a right bracket and an elastic unit; when the pedal-connecting component is in a closed state, the panel moves away from the upper bracket to transform the pedal-connecting component into an elastically spread state under a force on the panel in a downward direction; when the pedal-connecting component is in a spread state, the panel moves towards the upper bracket to transform the pedal-connecting component into an elastically closed state under a force on the panel in an obliquely-upward direction. The semi-automatic foot-pedal device of the present disclosure has a novel structure, and does not need a conventional motor system, so it saves the electric power and is safer to use.

Abstract: Provided are a pteridine ketone derivative used as an EGFR, BLK, and FLT3 inhibitor and applications thereof. Specifically, provided are a compound of the following formula I, a pharmaceutical composition containing the compound of the formula I, and use of compound in preparing medicine for treating diseases mediated by EGFR, BLK, or FLT3 or inhibiting EGFR, BLK, and FLT3.